Discounted Cash Flow
Anaptysbio, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $16.7m | $-4.3m | $-9.1m | -25.5% | $-1.62 |
| 2017 | $10.0m (-40.1%) | $-30.1m (-606.0%) | $-19.7m (-117.3%) | -300.7% (-1077.9%) | $-1.52 (6.2%) |
| 2018 | $5.0m (-50.0%) | $-61.7m (-105.0%) | $-49.6m (-151.3%) | -1233.1% (-310.1%) | $-2.50 (-64.5%) |
| 2019 | $8.0m (60.0%) | $-97.3m (-57.9%) | $-70.3m (-41.9%) | -1216.7% (1.3%) | $-3.60 (-44.0%) |
| 2020 | $75.0m (837.5%) | $-19.9m (79.5%) | $-14.7m (79.1%) | -26.6% (97.8%) | $-0.73 (79.7%) |
| 2021 | $63.2m (-15.8%) | $-57.8m (-190.0%) | $-47.3m (-221.1%) | -91.5% (-244.3%) | $-2.11 (-189.0%) |
| 2022 | $10.3m (-83.7%) | $-128.7m (-122.7%) | $-74.0m (-56.4%) | -1251.3% (-1267.8%) | $-4.57 (-116.6%) |
| 2023 | $17.2m (66.8%) | $-163.6m (-27.1%) | $-121.6m (-64.4%) | -953.7% (23.8%) | $-6.08 (-33.0%) |
| 2024 | $91.3m (432.0%) | $-145.2m (11.2%) | $-135.7m (-11.6%) | -159.1% (83.3%) | $-5.12 (15.8%) |
| 2025 | $234.6m (157.0%) | $-13.2m (90.9%) | $19.6m (114.5%) | -5.6% (96.5%) | $-0.46 (91.0%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.